ストックスクリーナーアプリを入手
0.09
147.25%
0.0536
前日終値:
$0.0364
開ける：
$0.0895
24時間の取引高:
35,056
Relative Volume:
1.00
時価総額：
$N/A
収益：
-
当期純損益:
$-8.28M
株価収益率:
-0.0384
EPS:
-2.3417
ネットキャッシュフロー:
$-3.40M
1週間 パフォーマンス:
+147.25%
1か月 パフォーマンス:
+101.70%
6か月 パフォーマンス:
+38.46%
1年 パフォーマンス:
-99.85%
1日の値動き範囲:
$0.0895
$0.11
1週間の範囲:
$0.0895
$0.11
52週間の値動き範囲:
$0.0341
$0.11
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Compare HEPA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.09 | 0 | 0 | -8.28M | -3.40M | -2.3417 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-07-20 | 再開されました | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc (HEPA) 最新ニュース
Hepion (OTC: HEPA) posts smaller Q1 loss but warns on going concern - Stock Titan
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Hepion Pharmaceuticals stock (US4268971032): Recent 27.9% surge draws attention - AD HOC NEWS
TradingKey - TradingKey
LoPriore and affiliates disclose 21.46% Hepion (HEPA) ownership stake - Stock Titan
Hepion (NASDAQ: HEPA) seeks shareholder approval for major 8M-share equity plan - Stock Titan
Hepion Pharmaceuticals director Michael J. Purcell buys $50,000 stock By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals director Michael J. Purcell buys $50,000 stock - Investing.com
Director Michael Purcell buys 1.25M Hepion (HEPA) shares - Stock Titan
Hepion Pharmaceuticals Stock (HEPA) Opinions on Executive Separation and ctRNA Licensing - Quiver Quantitative
Hepion director Appajosyula Sireesh buys $50,000 in stock By Investing.com - Investing.com South Africa
Hepion director Appajosyula Sireesh buys $50,000 in stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $50,000 in stock - Investing.com
Hepion Pharmaceuticals interim CEO Gary Stetz buys $50,000 in stock By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals: Executive chairman Vincent LoPriore buys $250,000 in stock - Investing.com Australia
Insider-linked funds buy 6.25M Hepion (HEPA) shares at $0.04 - Stock Titan
Director at Hepion (HEPA) makes 1,250,000-share open-market stock purchase - Stock Titan
Hepion (NASDAQ: HEPA) interim CEO linked to 1.25M-share open-market buy - Stock Titan
Hepion Pharmaceuticals Announces Private Placement Financing Agreement - TipRanks
Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04 - TradingView
Hepion Pharmaceuticals (HEPA) sells 17.5M shares in $700K private deal - Stock Titan
Hepion Pharmaceuticals, Inc. announced that it has received $0.7 million in funding - marketscreener.com
Hepion Pharmaceuticals enters separation agreement with former CEO Dr. Kaouthar Lbiati By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals enters separation agreement with former CEO Dr. Kaouthar Lbiati - Investing.com Australia
Hepion Finalizes CEO Separation Agreement Amid Leadership Transition - TipRanks
Hepion Pharmaceuticals (HEPA) CEO and director step down with severance deal - Stock Titan
Tech Rally: Is Hepion Pharmaceuticals Inc affected by consumer sentiment2026 Recap & Low Drawdown Investment Strategies - baoquankhu1.vn
Analyst Calls: Does SKLZ stock benefit from AI growth2026 EndofYear Setup & Growth Focused Investment Plans - baoquankhu1.vn
MusclePharm (OTCMKTS:MSLP) & Hepion Pharmaceuticals (NASDAQ:HEPA) Critical Contrast - Defense World
Hepion Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript - GuruFocus
HEPA (Hepion Pharmaceuticals) Non Operating Income : $-4.49 Mil (TTM As of Dec. 2025) - GuruFocus
HEPA (Hepion Pharmaceuticals) 3-Year Share Buyback Ratio : -434.70% (As of Dec. 2025) - GuruFocus
Value Recap: What are analysts price targets for Hepion Pharmaceuticals Inc2026 Pullback Review & Stock Timing and Entry Methods - baoquankhu1.vn
Is Hepion Pharmaceuticals Inc stock good for income investors2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
Hepion Pharmaceuticals Inc (HEPA) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
S P Trends: Can Hepion Pharmaceuticals Inc be the next market leader2026 Setups & Verified Entry Point Detection - baoquankhu1.vn
Hepion Pharmaceuticals CEO Resigns and Interim CEO Appointed – Official SEC Filing March 2026 - Minichart
Hepion Pharmaceuticals (NASDAQ: HEPA) CEO Gary Stetz submits Form 3 - Stock Titan
Hepion Pharmaceuticals (OTC: HEPA) CEO exits as board installs new leaders - stocktitan.net
Bearish Setup: How sensitive is Hepion Pharmaceuticals Inc to inflationTrade Exit Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Hepion Pharmaceuticals Stock (ISIN: US4268971032) Faces Uncertainty Amid Pipeline Delays and Biotech - AD HOC NEWS
Hepion (HEPA) exits liver drug program, pivots to diagnostics as cash window narrows - Stock Titan
HEPA: Net loss narrowed to $8.3M in 2025 as operations shifted to diagnostics, but no revenue was generated - TradingView
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Hepion Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
HEPA (Hepion Pharmaceuticals) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Gap Down: Should I buy Hepion Pharmaceuticals Inc. stock now2026 Earnings Impact & Daily Momentum Trading Reports - baoquankhu1.vn
Hepion Expands Liver Cancer Liquid Biopsy Theranostics Portfolio - TipRanks
Hepion Pharmaceuticals (HEPA) Enhances Early Cancer Detection wi - GuruFocus
ctRNA deal advances Hepion (OTCQB: HEPA) liquid biopsy strategy - Stock Titan
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to - GlobeNewswire
Hepion Pharmaceuticals Inc (HEPA) 財務データ
収益
当期純利益
現金流量
EPS
0.71%
大文字化:
|
ボリューム (24 時間):